Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06128148
Recruiting Phase 1

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

NCT06128148 · tracked via the Priya Life Science China tracker
Sponsor
Guangzhou JOYO Pharma Co., Ltd
Phase
Phase 1
Started
2022-05-04
Last updated
2025-07-14

Condition(s) studied

Protein Kinase InhibitorsOther Protocol Specified CriteriaLung NeoplasmsBrain Neoplasms

Investigational drug(s) / intervention(s)

JYP0322 50 mg qdJYP0322 100 mg qdJYP0322 200 mg qdJYP0322 100 mg bidJYP0322 150 mg bidJYP0322 200 mg bidJYP0322 150mg tid

JYP0322 50 mg qd: JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

JYP0322 100 mg qd: JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

JYP0322 200 mg qd: JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

JYP0322 100 mg bid: JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

JYP0322 150 mg bid: JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

JYP0322 200 mg bid: JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

JYP0322 150mg tid: JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.

Study summary

An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria * Adult patients age 18 years or older. * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a ROS1 molecular fusion. * Measurable disease according to RECIST version 1.1 * Life expectancy of at least 3 months * Other protocol specified criteria Key Exclusion Criteria: * Current participation in another therapeutic clinical trial. * Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption. * A history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug. * Known active infections (bacterial, viral including HIV positivity). * Other protocol specified criteria

Primary outcome measure(s)

  • The frequency and severity of adverse events of JYP0322 — From the date of informed consent through 30 days after the last dose of study drug, approximately up to 36 months.
    Evaluate the safety and tolerability of JYP0322 treatment. This will be assessed by: Incidence, nature, and severity of adverse events (AEs) during treatment, the proportion of patients requiring dose adjustment or permanent drug discontinuation.

Trial sites (1)

FacilityCityRegionStatus
Sun Yat-Sen University Cancer Center Guangzhou Guangdong Recruiting

More Guangzhou JOYO Pharma Co., Ltd trials in China

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) Recruiting
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Recruiting
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis Enrolling by invitation
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) Recruiting

Other trials for the same condition

Association of Psychological Distress in Patients With Lung Cancer Recruiting
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer Recruiting
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field Recruiting
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC Starting soon
Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06128148 on ClinicalTrials.gov ↗ ← All trials in China